As genetic tumor models have revealed important differences resulting from FAK loss versus inactivation of FAK activity (Dawson et al., 2021), FAK PROTAC compounds hold great promise as tools to decipher consequences of FAK or FAK–Pyk2 inhibition versus loss of expression. Here, PTK2 is linked to neoplasm.